Medtronic’s Extravascular ICD Stops Ventricular Arrhythmias In Pilot Trial
In a 21-patient first in-human pilot trial, Medtronic’s Extravascular Implantable Cardioverter Defibrillator (EV ICD) system successfully terminated induced ventricular arrhythmias in 89.5% of patients and achieved pacing capture in 95% of patients.
